Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology
To estimate the objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
To compare R-CHOP plus enzastaurin versus R-CHOP in terms of the elapsed progression-free survival (PFS) time measured in patients with intermediate and/or high-risk DLBCL receiving first-line treatme...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus
1. Day 6 of 6 days (6D) of pump reservoir in-use of Humalog is noninferior to Day 6 of 6D of pump reservoir in-use of insulin aspart with regards to 7-point daily mean SMBG (with a margin of 0.6 mmol/...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023
The primary objective of this study is to test the hypothesis that mean weight gain, as assessed by change from baseline, will be statistically significantly less for flexibly dosed LY2140023 (20, 40,...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Clinical Trial Testing the efficacy and Safety of Two Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer
Evaluate the efficacy of ramucirumab 12 mg/kg versus placebo, both in combination with paclitaxel, in terms of PFS
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients with Type 1 Diabetes
The primary objective of this study is to test the hypothesis that basal analog insulin lispro protamine suspension injected two times a day is noninferior to basal analog insulin detemir injected two...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Diabetic Macular Edema (diabetic eye disease)
To test the hypothesis that oral administration of 32 mg per day of ruboxistaurin will reduce, relative to placebo, the occurrence of SMVL (defined as a 15 letter or more decrease from baseline in bes...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study in Type 2 Diabetes Mellitus patients receiving blinded study drug to test a new study medication
To compare LY2409021 20 mg to placebo (PBO) on the change in hepatic fat fraction (HFF) from baseline (BL) to 6 months as measured by MRI in subjects with T2DM who are taking metformin (MET) and sulfo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis
The primary objective of this study is to compare the pharmacodynamic effect of a prasugrel 60 mg Loading Dose with a clopidogrel 600 mg Loading Dose, as assessed by change in mean maximal platelet ag...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Clinical Trial in Patients with Extensive Small Cell Lung Cancer
Cohort 1: To estimate the Overall Response Rate (ORR) when a dose of 105 mg/m2 LY2606368 every 14 days is administered to patients with ED-SCLC that have platinum-sensitive disease. Cohort 2: ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next